½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1361107

Ç×Ç÷ÀüÁ¦/Ç×ÀÀ°íÁ¦ : ±â¼ú ¹× ¼¼°è ½ÃÀå

Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: BCC Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 157 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è Ç×Ç÷ÀüÁ¦/Ç×ÀÀ°íÁ¦ ½ÃÀå ±Ô¸ð´Â 2023³â 316¾ï ´Þ·¯¿¡¼­ ¿¹Ãø ±â°£ µ¿¾È 7.9%ÀÇ CAGRÀ» ³ªÅ¸³»°í, 2028³â 462¾ï ´Þ·¯ ±Ô¸ð·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Æ®·Òºó ¾ïÁ¦Á¦ ºÎ¹®Àº 2023³â 246¾ï ´Þ·¯¿¡¼­ 2028³â 363¾ï ´Þ·¯ ±Ô¸ð·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, °°Àº ±â°£ µ¿¾È 8.1%ÀÇ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. Ç×Ç÷¼ÒÆÇÁ¦ ºÎ¹®Àº 2023³â 40¾ï ´Þ·¯ ±Ô¸ð¿¡¼­ 2028³â 58¾ï ´Þ·¯ ±Ô¸ð·Î CAGR 7.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°èÀÇ Ç×Ç÷ÀüÁ¦/Ç×ÀÀ°íÁ¦ ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå ¹× ±â¼ú °³¿ä, ½ÃÀå ¿µÇâ¿äÀÎ ¹× ½ÃÀå ±âȸ ºÐ¼®, ½ÃÀå ±Ô¸ð ÃßÀÌ ¹× ¿¹Ãø, °¢ ºÎ¹®º°/Áö¿ªº° »ó¼¼ ºÐ¼®, ±â¼ú ¹× ƯÇã µ¿Çâ, ESG Àü°³, °æÀï ±¸µµ, ÁÖ¿ä ±â¾÷ °³¿ä µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇص帳´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ¿ä¾à ¹× ÇÏÀ̶óÀÌÆ®

Á¦3Àå ½ÃÀå °³¿ä

  • ½ÉÇ÷°üÁúȯ °³¿ä
  • °ü»óµ¿¸Æ Áúȯ
  • Á׻󵿸ưæÈ­Áõ
  • Çù½ÉÁõ
  • ±Þ¼º ½É±Ù°æ»ö
  • ÀÇ·á °ü¸®
  • ¶óÀÌÇÁ½ºÅ¸ÀÏ º¯È­
  • ½Ä»ç ¼öÁ¤
  • ±Ý¿¬
  • ÀǾàÇ°
  • Ç×ÀÀ°íÁ¦ ¹× Ç×Ç÷¼ÒÆÇÁ¦
  • ÁÖ¿ä ÃËÁø¿äÀÎ
  • CVD °æ°¨À» ¸ñÀûÀ¸·Î ÇÑ ÀÀ°íÀÎÀÚ
  • ½ÉÇ÷°üÁúȯ ¼¼°è ºÎ´ã
  • ½ÉÇ÷°üÁúȯ ¼¼°èÀÇ °æÁ¦Àû ºÎ´ã
  • 2022³â ÁÖ¿ä ÀǾàÇ° ÆǸŠ½ÇÀû

Á¦4Àå ¼¼°èÀÇ Ç×ÀÀ°íÁ¦ ½ÃÀå

  • °³¿ä
  • Á¦Ç°
  • ÀúºÐÀÚ·® ÇìÆĸ°
  • °æ±¸ Ç×ÀÀ°íÁ¦(ºñŸ¹Î K ±æÇ×Á¦)
  • ¼¼°èÀÇ Ç×ÀÀ°íÁ¦ ½ÃÀå ¿¹Ãø

Á¦5Àå ¼¼°èÀÇ Ç×Ç÷¼ÒÆÇÁ¦ ½ÃÀå

  • °³¿ä
  • Á¦Ç°
  • °æ±¸ Ç×Ç÷¼ÒÆÇÁ¦
  • ¼¼°èÀÇ Ç×Ç÷¼ÒÆÇÁ¦ ½ÃÀå ¿¹Ãø

Á¦6Àå ¼¼°èÀÇ Æ®·Òºó ÀúÇØÁ¦ ½ÃÀå

  • °³¿ä
  • Á¦Ç°
  • Á÷Á¢Àû Æ®·Òºó ÀúÇØÁ¦
  • Ç÷Àü¿ëÇØ Á¦
  • Á÷Á¢ Á¦XaÀÎÀÚ ÀúÇØÁ¦
  • ¼¼°èÀÇ Æ®·Òºó ÀúÇØÁ¦ ½ÃÀå ¿¹Ãø

Á¦7Àå ¼¼°èÀÇ Ç×Ç÷ÀüÁ¦/Ç×ÀÀ°íÁ¦ ½ÃÀå : Áö¿ªº°

  • °³¿ä
  • ºÏ¹Ì
  • À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ±âŸ Áö¿ª

Á¦8Àå Ç×Ç÷ÀüÁ¦/Ç×ÀÀ°íÁ¦ ½ÃÀåÀÇ Áö¼Ó°¡´É¼º : ESG °üÁ¡

  • ESG : ¼­·Ð
  • Ç×Ç÷ÀüÁ¦/Ç×ÀÀ°íÁ¦ ½ÃÀå Áö¼Ó°¡´É¼º : ESG °üÁ¡À¸·ÎºÎÅÍ
  • ESG»óÀÇ ÁÖ¿ä ¹®Á¦
  • ESG¿¡ ´ëÇÑ ¼ÒºñÀÚ ÀǽÄ
  • ¾÷°èÀÇ ESG ÆÛÆ÷¸Õ½º ºÐ¼®
  • »ç·Ê ¿¬±¸
  • BCCÀÇ °á·Ð

Á¦9Àå ÀÓ»ó½ÃÇè°ú ƯÇã »óȲ

  • ÀÓ»ó½ÃÇè ºÐ¼®
  • ƯÇ㠺м®
  • ƯÇã : ¾ç¼öÀκ°

Á¦10Àå ÀμöÇÕº´(M&A) ¹× º¥Ã³ ÀÚ±Ý Á¶´Þ Àü¸Á

  • ÀμöÇÕº´(M&A)ºÐ¼®

Á¦11Àå °æÀï ±¸µµ

Á¦12Àå ±â¾÷ °³¿ä

  • BAYER AG
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • BRISTOL MYERS SQUIBB
  • DAIICHI SANKYO CO. LTD.
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON SERVICES INC.
  • MERCK & CO. INC.
  • PFIZER INC.
  • SANOFI

Á¦13Àå ºÎ·Ï

LSH 23.10.24

Highlights:

The global market for antithrombotic/anticoagulant drugs is estimated to grow from $31.6 billion in 2023 to reach $46.2 billion by 2028, at a compound annual growth rate (CAGR) of 7.9% from 2023 through 2028.

The global market for thrombin inhibitors is estimated to grow from $24.6 billion in 2023 to reach $36.3 billion by 2028, at a CAGR of 8.1% from 2023 through 2028.

The global market for antiplatelet drugs is estimated to grow from $4.0 billion in 2023 to reach $5.8 billion by 2028, at a CAGR of 7.8% from 2023 through 2028.

Report Scope:

This report discusses the implications of the trends mentioned above in the context of the current size and growth of the antithrombotic/anticoagulant drugs market, in global terms and by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the leading drug categories and the country offers breakdowns of the antithrombotic/anticoagulant drugs market.

Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the compound annual growth rate (CAGR) for the antithrombotic/anticoagulant drugs market.

This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific, and the Rest of the World. For market estimates, data are provided for 2022 as the base year, forecasted through 2023-2028.

Report Includes:

  • 59 data tables and 35 additional tables
  • Overview and an up-to-date analysis of the global markets for antithrombotic/anticoagulant drugs for the treatments of thrombotic (cardiovascular) disease
  • Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
  • Examination of the market potential for antithrombotic/anticoagulant drugs, and quantification of the global market for these drugs and its market segments and sub-segments over the next five years
  • Estimate of the actual market size and revenue forecast for the market, and corresponding market share analysis based on product type, application and region
  • In-depth information (facts and figures) pertaining to the market drivers, challenges, opportunities and prospects, as well as the technologies, regulatory scenarios and impact of COVID-19
  • A look at the major vendors in the global market for antithrombotic/anticoagulant drugs, and analysis of the healthcare industry structure, including market shares and recent mergers and acquisitions (M&A) activity
  • Review of key patent grants and a look at breakthrough innovations, novel products, upcoming trends and technologies, and emerging applications for cardiovascular treatments
  • Insight into the importance of ESG in the worldwide market, with a look at consumer attitudes, risks and opportunities assessment, and ESG practices followed by manufacturers and service providers
  • Identification of the major stakeholders, and analysis of the competitive landscape based on recent developments, key financials and segmental revenues, and operational integration
  • Profiles of the leading market players

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • What's New in This Report?
  • Scope of Report
  • Research Methodology
  • Information Sources
  • Geographic Breakdown

Chapter 2 Summary and Highlights

  • Market Outlook
  • Market Summary

Chapter 3 Market Overview

  • Overview of Cardiovascular Disease
  • Coronary Artery Disease
  • Atherosclerosis
  • Angina (Angina Pectoris)
  • Acute Myocardial Infarction
  • Medical Management
  • Lifestyle Changes
  • Diet Modification
  • Smoking Cessation
  • Pharmaceuticals
  • Anticoagulants and Antiplatelet Drugs
  • Major Drivers
  • Coagulation Factors Targeted to Reduce CVD
  • The Global Burden of Cardiovascular Disease
  • 2030 Global Burden of Cardiovascular Disease
  • The Global Economic Burden of Cardiovascular Disease
  • Sales Performance of Major Drugs in 2022

Chapter 4 Global Market for Anticoagulant Drugs

  • Overview
  • Products
  • Low Molecular Weight Heparin
  • Oral Anticoagulants (Vitamin K Antagonists)
  • Global Anticoagulant Drugs Market Forecast

Chapter 5 Global Market for Antiplatelet Drugs

  • Overview
  • Products
  • Oral Antiplatelets
  • Global Antiplatelet Drugs Market Forecast

Chapter 6 Global Market for Thrombin Inhibitors

  • Overview
  • Products
  • Direct Thrombin Inhibitors
  • Thrombolytic Agents
  • Direct Factor Xa Inhibitors
  • Global Thrombin Inhibitors Market Forecast

Chapter 7 Global Market for Antithrombotic/Anticoagulant Drugs by Region

  • Overview
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 8 Sustainability in the Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective

  • Introduction to ESG
  • Sustainability in Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective
  • Key ESG Issues
  • Consumer Attitudes Towards ESG
  • Industry ESG Performance Analysis
  • Case Study
  • Concluding Remarks from BCC

Chapter 9 Clinical Trials and Patent Landscape

  • Clinical Trials Analysis
  • Patent Analysis
  • Patent by Assignee

Chapter 10 M&A and Venture Funding Outlook

  • M&A Analysis

Chapter 11 Competitive Landscape

Chapter 12 Company Profiles

  • BAYER AG
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • BRISTOL MYERS SQUIBB
  • DAIICHI SANKYO CO. LTD.
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON SERVICES INC.
  • MERCK & CO. INC.
  • PFIZER INC.
  • SANOFI

Chapter 13 Appendix

  • Government Regulatory Agencies and Professional Organizations
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦